← Back to calculator
Extremely limited human data
BPC-157 is a synthetic peptide that is not FDA-approved and appears in the FDA's compounding-risk information; this page explains what it is, its regulatory status, and the open safety questions — with no dose recommendation.
Peptide Calculator X
Reconstitution / draw volume / syringe units / supply-chain
Arithmetic checks out. Confirm clinically, against the label, and against the actual vial before any use.
Independent check - dose mg / concentration mg/mL = volume. U-100 units = mL x 100.
Reverse: pick a dose and the units you want it to read, then calculate diluent to add.
BPC-157: reference record
| Regulatory status | Not FDA-approved; FDA reports limited safety information |
|---|---|
| Route | No established injectable treatment route |
| Dosing frequency | No established regimen |
| Published range | No established range |
| Evidence basis | Extremely limited human data |
| Common vial sizes | 5, 10 |
Sources
- U.S. Food & Drug Administration - fda.govBasis for the regulatory status, route, frequency and published range in the table above. Source last checked 2026-06-24
What is BPC-157?
BPC-157 is a synthetic peptide derived from a sequence reported in gastric juice. It is widely discussed for tissue repair, but that discussion rests on animal and laboratory work rather than on completed human efficacy trials.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved, and it appears in the FDA's information on bulk substances that may present significant safety risks in compounding. There is no approved product, indication or labeled use.
How is BPC-157 given?
There is no established injectable treatment route and no established regimen. Any route or schedule circulating online is not derived from an approved label or a completed human efficacy trial.
What are the known safety concerns with BPC-157?
Human data are extremely limited. A small intravenous safety observation in two participants is not efficacy evidence and should not be extrapolated to subcutaneous self-use. The FDA has reported limited safety information for this substance.
A 2-person IV safety pilot used 10 mg then 20 mg; this does not establish an effective or SC dose
No default dose. Enter a value only from an approved research protocol or licensed prescriber/pharmacy instructions.
n=2 IV safety observation is not efficacy evidence and should not be extrapolated to subcutaneous self-use.
Supply-chain quality · Finnrick
Avg quality score
6.2
/10
Purity range
96.49
–
99.95
%
Qty divergence
±
70
%
Vendors · samples
86
·
606
Common vial sizes
5, 10
mg
Test window
Dec 2024 - Jun 2026
Related calculators & comparisons
COMPARISONS
Browse all peptides →